Lidocaine carcinogenicity
This article was originally published in The Tan Sheet
Executive Summary
FDA's Anesthetic and Life Support Drugs Advisory Committee will discuss reports on the carcinogenicity of 2,6 xylidine (2,6 dimenthylaniline), a metabolite of lidocaine, at an Aug. 23 meeting. The Nonprescription Drug Manufacturers Association has been asked by FDA to make a presentation at the session, which will begin at 9 a.m. at the Silver Spring, Md. Holiday Inn, 8777 Georgia Avenue.